an anti-inflammatory drug would reduce the risk of complications from the virus

A large clinical study shows that colchicine, an anti-inflammatory drug, is effective in treating Covid-19 and reducing the risk of complications related to the disease, announced the Montreal Heart Institute (ICM).

The positive results of the COLCORONA study constitute a “major scientific discovery”, which makes colchicine – a potent anti-inflammatory drug used in the treatment of gout – “the first oral drug in the world that could treat pre-phase patients. -hospitable, “said the ICM in a statement released late Friday evening.

The results of the study “demonstrated that colchicine reduced the risk of death or hospitalization in patients with Covid-19 by 21% compared to placebo””, underlines the ICM.

25% reduction in hospitalizations

The study, conducted in Canada, the United States, Europe, South America and South Africa, involved 4,488 patients.

In 4,159 of these patients – whose diagnosis of Covid-19 was proven by a nasopharyngeal test (PCR) – colchicine “resulted in reductions in hospitalizations by 25%, in the need for mechanical ventilation by 50%, and 44% of deaths “, argues the institute.

- Advertisement -

Colchicine treatment is effective in preventing the phenomenon of “major inflammatory storm” and reducing the risk of complications related to Covid-19, explained Dr Jean-Claude Tardif, director of the ICM Research Center and principal investigator of the COLCORONA study.

“”We are pleased to offer the world’s first oral drug whose use could have a significant impact on public health and potentially prevent complications from Covid-19 in millions of patients,” he said.

>> To read also: When the sequelae of Covid-19 last: what the research says

“Effectiveness of colchicine”

“Big news: a Quebec study shows the effectiveness of colchicine to treat Covid-19“”, welcomed the Prime Minister of Quebec François Legault in a tweet.

The COLCORONA study was conducted “without contact”, with patients with Covid-19 who were not hospitalized at the time of inclusion, with at least one risk factor for complications.

“”This is the largest study in the world testing a drug administered orally in non-hospitalized patients with Covid-19,” says the ICM.

These were the details of the news an anti-inflammatory drug would reduce the risk of complications from the virus for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at en24 news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV How close Saudi-Malaysian cooperation led to a drug bust
NEXT Youth join mainstream as India unveils development initiatives in Jammu and Kashmir